I am excited to join Ginkgos board of directors at such a pivotal time for the company,
said Reshma Kewalramani, M.D., FASN, Chief Executive Officer and President at Vertex. Ginkgo has built a unique and innovative company over the past thirteen years, and I am particularly excited by the companys broad platform which holds
the potential to meaningfully transform multiple fields from agriculture to energy to life sciences. Im looking forward to working with the Ginkgo team to build out these capabilities even further as they navigate their next stage of
growth.
Dr. Kewalramani plans to join as the eighth board member for Ginkgo Bioworks. Current board members include Dr. Jason Kelly, co-founder and CEO of Ginkgo Bioworks; Dr. Reshma Shetty, co-founder, President and Chief Operating Officer of Ginkgo Bioworks; Marijn Dekkers, founder and chairman of
Novalis LifeSciences LLC; Christian Henry, President and CEO of Pacific Biosciences; and Shyam Sankar, Chief Operating Officer and Executive Vice President of Palantir. Dr. Kewalramani plans to join the board immediately after the close of
Ginkgos business combination with Soaring Eagle Acquisition Corp., along with Harry Sloan, Chairman and CEO of Eagle Equity Partners II, LLC and Dr. Arie Belldegrun, MD, FACS, Executive Chairman and
Co-Founder of Allogene Therapeutics.
About Ginkgo Bioworks
Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The companys platform is enabling biotechnology
applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo is also actively supporting a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery. In May 2021, Ginkgo announced a business combination with Soaring Eagle Acquisition Corp. (Nasdaq:SRNG), which, if completed, will
result in Ginkgo, through a parent entity, Ginkgo Bioworks Holdings, Inc., becoming a public company. The transaction is expected to close in the third quarter of 2021, subject to regulatory and shareholder approvals, and other customary closing
conditions. For more information, visit www.ginkgobioworks.com.
ADDITIONAL LEGAL INFORMATION
Forward-Looking Statements Legend
This document contains
certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed transaction between Ginkgo and Soaring Eagle Acquisition Corp. (SRNG), including statements regarding the benefits of the
transaction, the anticipated timing of the transaction, the services offered by Ginkgo and the markets in which it operates, and Ginkgos projected future results. These forward-looking statements generally are identified by the words
believe, project, expect, anticipate, estimate, intend, strategy, future, opportunity, plan, may, should,
will, would, will be, will continue, will likely result, and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are
based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not
limited to: (i) the risk that the transaction may not be completed in a